4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Psoriatic Arthritis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 640 ongoing clinical trials involving Psoriatic Arthritis
Of the 640 trials,278 trials are in Phase III
Furthermore, 187 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Psoriatic Arthritis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Psoriatic Arthritis, a musculoskeletal disorder. The largest number of ongoing clinical trials for Psoriatic Arthritis is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Psoriatic Arthritis-related drug trials.

Johnson & Johnson: The leading ongoing Psoriatic Arthritis related clinical trial sponsor

Johnson & Johnson is the top sponsor for Psoriatic Arthritis-related ongoing clinical trials.

Novartis AG, Amgen Inc, Bristol-Myers Squibb Co, University Hospital Erlangen, and Pfizer Inc are among other notable clinical trial sponsors involved in Psoriatic Arthritis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Psoriatic Arthritis

Adalimumab (Humira), Ustekinumab (Stelara), and Etanercept (Enbrel, Enbrel PFS) are among the key marketed drugs involving Psoriatic Arthritis.

Adalimumab (Humira) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). It functions via Tumor Necrosis Factor (Cachectin or TNF Alpha or Tumor Necrosis Factor Ligand Superfamily Member 2 or TNF a or TNF) Inhibitor mechanism of action. Adalimumab is formulated as an injection for subcutaneous route of administration. Adalimumab is marketed for the treatment of several indications including Pyoderma Gangrenosum, Axial Spondyloarthritis, Hidradenitis Suppurativa, Uveitis, Ankylosing Spondylitis (Bekhterev's Disease), Psoriatic Arthritis, Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Crohn's Disease (Regional Enteritis), Anterior Uveitis, Behcet Disease, Intermediate Uveitis, Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), and Posterior Uveitis. It was first approved in 2002 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including AbbVie Inc, Eisai Co Ltd, and Abbott Laboratories.

Ustekinumab (Stelara) is a human monoclonal antibody used as immunosuppressant. It functions via Interleukin 12 Subunit Beta (Cytotoxic Lymphocyte Maturation Factor 40 kDa Subunit or CLMF p40 or IL12 Subunit p40 NK Cell Stimulatory Factor Chain 2 or IL12B) Inhibitor; Interleukin 23 Subunit Alpha (Interleukin 23 Subunit p19 or IL23A) Inhibitor mechanism of action. It is produced by a recombinant DNA technology. It is formulated as a injectable solution for injection, powder for solution and solution for injection in pre-filled syringe and is administered by subcutaneous route and intravenous administration and injectable concentrate solution for subcutaneous route of administration. Ustekinumab is marketed for the treatment of several indications including Psoriatic Arthritis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), and Plaque Psoriasis (Psoriasis Vulgaris). Ustekinumab was first approved in 2008 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Janssen Biotech Inc, J-C Health Care Ltd, and Johnson & Johnson.